CanFite BioPharma For Profit
Can-Fite BioPharma is an Israeli biopharmaceutical company that specializes in the discovery and clinical development of small molecule drugs for oncology, inflammatory, and metabolic diseases. The company's platform technology uses the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target, which is highly expressed in pathological body cells. Can-Fite's compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects. The company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development. Contact info: N/A.
%20.jpg)
Employee Number:
1-10
Investors Number:
4
Funding Status:
IPO
Headquarters:
Petah Tiqva, HaMerkaz, Israel
Technology:
Drug development
Estimated Revenue:
$1M to $10M
Founded Date:
1994-01-01
Last Funding Type:
Post-IPO Equity
Investor Type:
Company
Total Funding:
$51.4M
Number Of Exists:
Post-IPO Equity
Investment Stage:
N/A
Industry:
PharmTech